SCHEMBL5020207

SCHEMBL5020207

c1ccc2oc(-c3cnn[nH]3)cc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
METAP2 P50579 1/20 0.50
ADRA2A P08913 2/20 0.46
MAOB P27338 4/20 0.45
MAOA P21397 3/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
HSD17B10 Q99714 1/20 0.45
NISCH Q9Y2I1 1/20 0.45
MAPT P10636 2/20 0.44
GRM4 Q14833 1/20 0.42
ALOX5 P09917 1/20 0.41
KDM5A P29375 1/20 0.41
KDM4C Q9H3R0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL103158 0.73 MAOB (0.63) NPC1RAB9AMETAP2ADRA2AMAOB
SCHEMBL30036439 0.73 MAOB (0.63) NPC1RAB9AMETAP2ADRA2AMAOB
SCHEMBL17843529 0.70 NPC1 (0.56) NPC1RAB9AMETAP2ADRA2AMAOB
SCHEMBL30561833 0.70 MAOB (0.55) NPC1RAB9AMETAP2ADRA2AMAOB
SCHEMBL31652715 0.70 ADRA2A (0.54) NPC1RAB9AMETAP2ADRA2AMAOB
SCHEMBL2150499 0.69 MAOB (0.59) NPC1RAB9AMETAP2ADRA2AMAOB
SCHEMBL927135 0.69 RAB9A (0.54) NPC1RAB9AMETAP2ADRA2AMAOB
SCHEMBL6989535 0.69 NPC1 (0.54) NPC1RAB9AMETAP2ADRA2AMAOB
SCHEMBL9052695 0.69 NPC1 (0.54) NPC1RAB9AMETAP2ADRA2AMAOB
SCHEMBL2149640 0.68 MAOB (0.57) NPC1RAB9AMETAP2ADRA2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483147-A1 METALLOENZYME INHIBITOR COMPOUNDS Innocrin Pharmaceuticals, Inc. (US) 2019-05-15 EP disclosed
US-20180221364-A1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS, INC. 2018-08-09 US disclosed
US-20140121248-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-05-01 US disclosed
US-8623892-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-01-07 US disclosed
US-20130184309-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2013-07-18 US disclosed
US-8389543-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2013-03-05 US disclosed
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed
WO-2012064943-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121248-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NPC1 565/4885RAB9A 2721/4885METAP2 60/4885
US-20180221364-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NPC1 565/4885RAB9A 2721/4885METAP2 60/4885
US-20130184309-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NPC1 565/4885RAB9A 2721/4885METAP2 60/4885
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NPC1 565/4885RAB9A 2721/4885METAP2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.